From the FDA: For the first time in more than 20 years of regulating mammography facilities, the FDA has announced important new steps to modernize breast cancer screening and help empower patients with information when they are considering important decisions regarding their breast health care. The amendment includes the requirement of breast density reporting to both patients and referring health providers. DBI is analyzing the proposed language and will be submitting comments to the FDA during the designated “open for public comment” period which concludes June 26, 2019. To read the rule, click HERE.
